Promega's Cookie Policy

We use cookies and similar technologies to make our website work, run analytics, improve our website, and show you personalized content and advertising. Some of these cookies are essential for our website to work. For others, we won’t set them unless you accept them. To find out more about cookies and how to manage cookies, read our Cookie Policy.

A Homogenous PBMC ADCC Bioassay Enables Bridging Studies with ADCC Reporter Bioassays in Immunotherapy Monoclonal Antibody Development

Part # PS369


Pete Stecha, Julia Gilden, Jun Wang, Denise Garvin, Jim Hartnett, Frank Fan, Mei Cong and Zhijie Jey Cheng
Promega Corporation, 2800 Woods Hollow Rd, Madison, WI 53711

Antibody-dependent cellular cytotoxicity (ADCC) is a key mechanism of action for therapeutic antibodies. Previously, we developed a surrogate ADCC Reporter Bioassay using engineered reporter effector cells and demonstrated its suitability for antibody product release and stability study. Here we describe an improved ADCC assay using PBMC and engineered HiBiT-target cells for use in antibody early characterization and to enable ADCC method bridging studies.

Printed in USA.